Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 18/20 | 0.85 |
| ▸ | HTR2A | P28223 | 5/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | CCR2 | P41597 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329675 | 0.93 | CCR3 (0.91) | CCR3HTR2AALOX15 | |
| SCHEMBL6330906 | 0.92 | CCR3 (0.87) | CCR3HTR2AALOX15 | |
| SCHEMBL6333126 | 0.92 | CCR3 (0.84) | CCR3HTR2AALOX15 | |
| SCHEMBL6335910 | 0.92 | CCR3 (1.00) | CCR3HTR2AALOX15 | |
| SCHEMBL6333168 | 0.88 | CCR3 (1.00) | CCR3HTR2A | |
| SCHEMBL6328930 | 0.88 | CCR3 (0.85) | CCR3HTR2AALOX15 | |
| SCHEMBL6337248 | 0.88 | CCR3 (0.85) | CCR3HTR2AALOX15 | |
| SCHEMBL6331405 | 0.87 | CCR3 (0.70) | CCR3HTR2A | |
| SCHEMBL6333220 | 0.86 | CCR3 (0.82) | CCR3HTR2AALOX15 | |
| SCHEMBL6336125 | 0.86 | CCR3 (0.92) | CCR3HTR2ACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058960-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-25 | — | — | US | claimed |
| EP-1140086-A4 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARM CO (US) | 2002-04-03 | — | — | EP | claimed |
| EP-1140086-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035451-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| US-6906066-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040058960-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-25 | — | — | US | disclosed |
| US-6605623-B1 | Prevention of asthma and other allergic diseases | BRISTOL-MYERS SQUIBB PHARMA CO. | 2003-08-12 | — | — | US | disclosed |
| EP-1140086-A4 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARM CO (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1140086-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035451-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058960-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | CCR3 1/4885HTR2A 1608/4885ALOX15 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.